Equity Overview
Price & Market Data
Price: $27.84
Daily Change: $0.00 / 0.00%
Daily Range: $0 - $0
Market Cap: $1,820,953,856
Daily Volume: 0
Performance Metrics
1 Week: 2.02%
1 Month: 7.45%
3 Months: 11.90%
6 Months: 19.03%
1 Year: 110.8%
YTD: 0.32%
Company Details
Employees: 129
Sector: Health technology
Industry: Biotechnology
Country: Netherlands
Details
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist for the treatment of attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), as well as in Phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.